Veltassa

Relypsa Inc (NASDAQ: RLYP) confirmed that the FDA has approved patiromer Veltassa for the treatment of hyperkalemia. However, a misunderstanding has created a buying opportunity, Wedbush analysts assured in a report issued Thursday. The stock was down more than 18 percent on Thursday trading...